Gilead Sciences (NASDAQ:GILD) Price Target Raised to $102.00 at BMO Capital Markets

Gilead Sciences (NASDAQ:GILD) had its price objective boosted by BMO Capital Markets from $94.00 to $102.00 in a report released on Thursday,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

Several other equities analysts have also issued reports on the company. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Piper Sandler upped their price objective on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday. Royal Bank of Canada upped their price objective on Gilead Sciences from $75.00 to $81.00 and gave the company a “sector perform” rating in a research note on Thursday. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday. Finally, Cantor Fitzgerald upped their price objective on Gilead Sciences from $70.00 to $80.00 and gave the company a “neutral” rating in a research note on Thursday. Eleven equities research analysts have rated the stock with a hold rating, ten have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $91.50.

Gilead Sciences Trading Down 1.4 %

Shares of GILD opened at $96.57 on Thursday. Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $98.32. The company has a quick ratio of 0.95, a current ratio of 1.11 and a debt-to-equity ratio of 1.18. The firm has a market capitalization of $120.23 billion, a price-to-earnings ratio of 1,073.00, a P/E/G ratio of 3.36 and a beta of 0.17. The stock’s 50-day moving average price is $85.30 and its 200 day moving average price is $75.09.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period in the previous year, the company posted $2.29 earnings per share. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. As a group, research analysts predict that Gilead Sciences will post 4.34 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.19%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences’s dividend payout ratio is 3,422.22%.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of the stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 62,437 shares of company stock valued at $5,374,825. 0.16% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in GILD. LPL Financial LLC increased its position in shares of Gilead Sciences by 7.4% in the 3rd quarter. LPL Financial LLC now owns 1,137,381 shares of the biopharmaceutical company’s stock valued at $95,358,000 after buying an additional 78,839 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Gilead Sciences by 38.2% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 764,520 shares of the biopharmaceutical company’s stock valued at $64,097,000 after buying an additional 211,493 shares in the last quarter. Cornerstone Advisors LLC increased its position in shares of Gilead Sciences by 6.0% in the 3rd quarter. Cornerstone Advisors LLC now owns 68,400 shares of the biopharmaceutical company’s stock valued at $5,735,000 after buying an additional 3,900 shares in the last quarter. Citizens Financial Group Inc. RI increased its position in shares of Gilead Sciences by 5.6% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 6,321 shares of the biopharmaceutical company’s stock valued at $530,000 after buying an additional 337 shares in the last quarter. Finally, EagleClaw Capital Managment LLC increased its position in shares of Gilead Sciences by 3.7% in the 3rd quarter. EagleClaw Capital Managment LLC now owns 9,060 shares of the biopharmaceutical company’s stock valued at $760,000 after buying an additional 325 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.